• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·603222.SS
Share

Chimin Health Management Co., Ltd. Stocks

CN¥ 9.58Last Updated 15.07.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

CN¥ 765.63M

CN¥ 9.58
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Chimin Health Management Co., Ltd., formerly known as Zhejiang Chimin Pharmaceutical Co.,Ltd., is a Chinese enterprise specializing in the research, production, and distribution of pharmaceuticals for human use and medical apparatus. Its product offerings include diverse medical packaging options, such as non-PVC soft bags with various valve configurations (e.g., double-tube double valves, single valves, single-tube double valves), plastic bottles, and other specialized containers. The company also supplies an extensive array of injection and infusion devices, encompassing safety syringes, safety injection needles, sterile syringes, irrigators, dispensers, insulin syringes, as well as standard and precision filter infusion sets. Beyond these, Chimin Health Management provides in-vitro diagnostic products, hemodialysis supplies, and delivers medical services. The firm was established in 1996 and maintains its principal operations in Huangyan, China.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 08:30

Nuclear fusion projects have raised a record $4.5 billion. Is a new boom underway?

15.07.2026 07:30

Chinese AI developer DeepSeek has begun preparations for an IPO next year — Bloomberg

15.07.2026 03:24

Lucid's stock plummeted following news of a possible bankruptcy. At one point, it was down 57%.

15.07.2026 02:16

"The Prisoner's Dilemma": JPMorgan Warns of a Threat to Coinbase and Circle's Profits

15.07.2026 01:24

Inflation data pushed the indices higher. Software developers are under pressure again

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026